Movement Alert|Iovance Biotherapeutics, Inc. Falls 5.06% in Regular Trading, Pullback Follows Lack of Fresh Catalysts

Market Focus11-21 02:41

On November 21, Iovance Biotherapeutics, Inc. fell 5.06% in Regular Trading, trading at $6.935 per share, with turnover of $45.10 million.

The latest company update was a conference participation announcement disclosed on November 13, which did not include new clinical, regulatory, or financial developments, leaving the shares without a fresh catalyst.

Earlier, the company reported third-quarter EPS of fall $0.05, better than consensus expectations for a wider loss, while revenue rose to $121.5 million from $67.5 million a year earlier and topped market forecasts. Management also reaffirmed full-year product revenue guidance of $410 million to $420 million. Despite those stronger reported figures, the recent news flow has been limited mainly to event appearances rather than new operating milestones.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment